The global medical image analysis software market is projected to grow from USD 4.35 billion in 2026 to USD 6.42 billion by 2031, representing a compound annual growth rate of 8.1%, according to MarketsandMarkets. North America held the largest regional share in 2025 at 38.4%, while integrated software accounted for 64.5% of the market. AI-enabled technology is expected to record the fastest growth, with a projected 8.6% CAGR. Demand is being supported by the need for AI-assisted detection, reconstruction, segmentation, reporting and clinical decision support across CT, MRI, ultrasound and mammography. Rising imaging volumes, radiologist shortages and more complex scans are encouraging hospitals and imaging centers to adopt automation. The market faces constraints including high validation costs, data privacy concerns, reliance on legacy PACS/RIS systems (medical imaging and information systems) and inconsistent reimbursement. North America benefits from the U.S. FDA (U.S. medical-device regulator) clearance framework for AI/ML-enabled devices; the FDA’s AI-Enabled Medical Device List contained 1,357 authorized devices as of January 2026, including 1,039 radiology devices, or 77% of the total. The release also identifies investment and acquisition activity involving Aidoc Medical Ltd., Subtle Medical, Inc., CARPL.ai, Gleamer, Intelerad and iCAD, while naming major industry participants including Siemens Healthineers, GE HealthCare, Koninklijke Philips, Canon Medical Systems and FUJIFILM.